

Coverage & Billing Information for the 2023 Quarterly Code Update

BACKGROUND

Iowa Medicaid has reviewed the Q1 2023 Billing Code Update to determine coverage and billing guidelines. The Iowa Medicaid coverage and billing information provided in this bulletin is effective January 1, 2023. This bulletin serves as a notice of the following information:

Table 1

- New Current Procedural Terminology (CPT[®]) and Healthcare Common Procedure Coding System (HCPCS) codes included in the Q1 2023 code update. Coverage and billing information for these codes applies to dates of service on or after **January 1, 2023**.

Table 2

- New Current Dental Terminology (CDT[®]) codes included in the Q1 2023 code update. Coverage and billing information for these codes applies to dates of service on or after **January 1, 2023**.

Table 3

- International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes. Coverage and billing for these codes applies to dates of service on or after **April 1, 2023**.

Table 4

- International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) codes. Coverage and billing for these codes applies to dates of service on or after **April 1, 2023**.

Table 5

- Modifiers included in the Q1 2023 code update. Coverage and billing information for these codes applies to dates of service on or after **January 1, 2023**.

Table 6

- CPT[®], CDT[®], & HCPCS codes that require Pre-Pay or Post-Pay claim review for Fee For Service (FFS) (traditional Medicaid) effective **January 1, 2023**.

Table 7

- Non-Covered Codes - CPT[®], CDT[®], HCPCS, ICD-10-CM & ICD-10-PCS codes that have been thoroughly reviewed and Iowa Medicaid has decided not to cover effective **January 1, 2023**.

Table 8

- Deleted Codes - CPT[®], CDT[®], HCPCS, ICD-10-CM & ICD-10-PCS codes that have been discontinued effective **December 31, 2022**.

The standard global billing procedures and edits apply to the new codes unless special billing guidance is otherwise noted. Reimbursement, prior authorization (PA), and billing information apply to services delivered under the fee-for-service (FFS) delivery system. Questions about FFS PA should be directed to Iowa Medicaid Provider Services at 1-800-338-7909 or via email at imeproviderservices@dhs.state.ia.us.

Managed Care Organization (MCOs) establish and publish reimbursement, PA, and billing information within the managed care delivery system. Questions about managed care PA should be directed to the MCO with which the member is enrolled.

Amerigroup Iowa, Inc.:

- Provider Services: 1-800-454-3730
- Provider email: iowamedicaid@amerigroup.com
- Website: <https://providers.amerigroup.com/ia>

Iowa Total Care:

- Provider Services: 1-833-404-1061
- Provider email: Providers may send email using their account on the ITC website.
- Website: <https://www.iowatotalcare.com>

The **QI 2023** code update may include modifications to descriptions for some existing HCPCS/CPT codes. These modifications are available for reference or download from the CMS website at www.cms.gov.

The **QI** code update also includes a list of deleted codes. These codes are available for reference or download from the CMS website at cms.gov. If there is a replacement code, Iowa Medicaid has added the replacement code for which there were deleted codes effective as of **December 31, 2023**.

Medically Unlikely Edits are the maximum units of service that a provider would report under most circumstances for a single beneficiary on a single date of service. The **max units** listed in the tables below are derived from the quarterly [Medicaid NCCI Edits](#) released by CMS.

Iowa Medicaid will update the fee schedule as rates become available.

Table I – CPT® & HCPCS Codes

[Back to top](#)

| Code | Desc | Effective Date | Special Billing Information |
|--------------|---|----------------|-----------------------------|
| 15778 | Implantation of absorbable mesh or other prosthesis for delayed closure of defect(s) (i.e., external genitalia, perineum, abdominal wall) due to soft tissue infection or trauma | 1/1/2023 | Max Units: 1 |
| 15853 | Removal of sutures or staples not requiring anesthesia (List separately in addition to E/M code) | 1/1/2023 | Max Units: 1 |
| 15854 | Removal of sutures and staples not requiring anesthesia (List separately in addition to E/M code) | 1/1/2023 | Max Units: 1 |
| 33900 | Percutaneous pulmonary artery revascularization by stent placement, initial; normal native connections, unilateral | 1/1/2023 | Max Units: 1 |
| 33901 | Placement of stent in pulmonary arteries with normal anatomical connections, on both sides of body | 1/1/2023 | Max Units: 1 |
| 33902 | Percutaneous pulmonary artery revascularization by stent placement, initial; abnormal connections, unilateral | 1/1/2023 | Max Units: 1 |
| 33903 | Placement of stent in pulmonary arteries with abnormal anatomical connections, on both sides of body | 1/1/2023 | Max Units: 1 |
| 33904 | Placement of additional stent in pulmonary artery | 1/1/2023 | Max Units: 1 |
| 49591 | Repair of anterior abdominal hernia(s) (i.e., epigastric, incisional, ventral, umbilical, spigelian), any approach (i.e., open, laparoscopic, robotic), initial, including implantation of mesh or other prosthesis when performed, total length of defect(s); less than 3 cm, reducible | 1/1/2023 | Max Units: 1 |
| 49592 | Repair of anterior abdominal hernia(s) (i.e., epigastric, incisional, ventral, umbilical, spigelian), any approach (i.e., open, laparoscopic, robotic), initial, including implantation of mesh or other prosthesis when performed, total length of defect(s); less than 3 cm, incarcerated or strangulated | 1/1/2023 | Max Units: 1 |
| 49593 | Repair of anterior abdominal hernia(s) (i.e., epigastric, incisional, ventral, umbilical, spigelian), any approach (i.e., open, laparoscopic, robotic), initial, including implantation of mesh or other prosthesis when performed, total length of defect(s); 3 cm to 10 cm, reducible | 1/1/2023 | Max Units: 1 |
| 49594 | Repair of anterior abdominal hernia(s) (i.e., epigastric, incisional, ventral, umbilical, spigelian), any approach (i.e., open, laparoscopic, robotic), initial, including implantation of mesh or other prosthesis when performed, total length of defect(s); 3 cm to 10 cm, incarcerated or strangulated | 1/1/2023 | Max Units: 1 |
| 49595 | Repair of anterior abdominal hernia(s) (i.e., epigastric, incisional, ventral, umbilical, spigelian), any approach (i.e., open, laparoscopic, robotic), initial, including implantation of mesh or other prosthesis when performed, total length of defect(s); greater than 10 cm, reducible | 1/1/2023 | Max Units: 1 |
| 49596 | Repair of anterior abdominal hernia(s) (i.e., epigastric, incisional, ventral, umbilical, spigelian), any approach (i.e., open, laparoscopic, robotic), initial, including implantation of mesh or other prosthesis when performed, total length of defect(s); greater than 10 cm, incarcerated or strangulated | 1/1/2023 | Max Units: 1 |
| 49613 | Repair of anterior abdominal hernia(s) (i.e., epigastric, incisional, ventral, umbilical, spigelian), any approach (i.e., open, laparoscopic, robotic), recurrent, including implantation of mesh or other prosthesis when performed, total length of defect(s); less than 3 cm, reducible | 1/1/2023 | Max Units: 1 |

| | | | |
|--------------|---|----------|--------------|
| 49614 | Repair of anterior abdominal hernia(s) (i.e., epigastric, incisional, ventral, umbilical, spigelian), any approach (i.e., open, laparoscopic, robotic), recurrent, including implantation of mesh or other prosthesis when performed, total length of defect(s); less than 3 cm, incarcerated or strangulated | 1/1/2023 | Max Units: 1 |
| 49615 | Repair of anterior abdominal hernia(s) (i.e., epigastric, incisional, ventral, umbilical, spigelian), any approach (i.e., open, laparoscopic, robotic), recurrent, including implantation of mesh or other prosthesis when performed, total length of defect(s); 3 cm to 10 cm, reducible | 1/1/2023 | Max Units: 1 |
| 49616 | Repair of anterior abdominal hernia(s) (i.e., epigastric, incisional, ventral, umbilical, spigelian), any approach (i.e., open, laparoscopic, robotic), recurrent, including implantation of mesh or other prosthesis when performed, total length of defect(s); 3 cm to 10 cm, incarcerated or strangulated | 1/1/2023 | Max Units: 1 |
| 49617 | Repair of anterior abdominal hernia(s) (i.e., epigastric, incisional, ventral, umbilical, spigelian), any approach (i.e., open, laparoscopic, robotic), recurrent, including implantation of mesh or other prosthesis when performed, total length of defect(s); greater than 10 cm, reducible | 1/1/2023 | Max Units: 1 |
| 49618 | Repair of anterior abdominal hernia(s) (i.e., epigastric, incisional, ventral, umbilical, spigelian), any approach (i.e., open, laparoscopic, robotic), recurrent, including implantation of mesh or other prosthesis when performed, total length of defect(s); greater than 10 cm, incarcerated or strangulated | 1/1/2023 | Max Units: 1 |
| 49621 | Repair of sliding hernia next to stoma | 1/1/2023 | Max Units: 1 |
| 49622 | Repair of parastomal hernia, any approach (i.e., open, laparoscopic, robotic), initial or recurrent, including implantation of mesh or other prosthesis, when performed; incarcerated or strangulated | 1/1/2023 | Max Units: 1 |
| 49623 | Removal of total or near total non-infected mesh or other prosthesis at the time of initial or recurrent anterior abdominal hernia repair or parastomal hernia repair, any approach (i.e., open, laparoscopic, robotic) (List separately in addition to code for primary procedure) | 1/1/2023 | Max Units: 1 |
| 55867 | Laparoscopy, surgical prostatectomy, simple subtotal (including control of postoperative bleeding, vasectomy, meatotomy, urethral calibration and/or dilation, and internal urethrotomy), includes robotic assistance, when performed | 1/1/2023 | Max Units: 1 |
| 76883 | Ultrasound, nerve(s) and accompanying structures throughout their entire anatomic course in one extremity, comprehensive, including real-time cine imaging with image documentation, per extremity | 1/1/2023 | Max Units: 4 |
| 84433 | Thiopurine S-methyltransferase (TPMT) | 1/1/2023 | Max Units: 1 |
| 87467 | Measurement of Hepatitis B surface antigen (HBsAg) | 1/1/2023 | Max Units: 1 |
| 87468 | Infectious agent detection by nucleic acid (DNA or RNA); Ana plasma phagocytophilum, amplified probe technique | 1/1/2023 | Max Units: 1 |
| 87469 | Detection of Babesia microtia by amplified nucleic acid probe technique | 1/1/2023 | Max Units: 1 |
| 87478 | Detection of Babesia Borrelia miyamotoi by amplified nucleic acid probe technique | 1/1/2023 | Max Units: 1 |
| 87484 | Detection of Ehrlichia chaffeensis by amplified nucleic acid probe technique | 1/1/2023 | Max Units: 1 |

| | | | |
|---------------|--|------------|--------------|
| 91312* | Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid19]) vaccine, mrna-lnp, bivalent spike protein, preservative free, 30 mcg/0.3 ml dosage, trissucrose formulation, for intramuscular use | 8/31/2022 | |
| 91313* | Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid19]) vaccine, mrna-lnp, spike protein, bivalent, preservative free, 50 mcg/0.5 ml dosage, for intramuscular use | 8/31/2022 | |
| 91314* | Sarscov2 vac bvl 25mcg/.25ml | 10/12/2022 | |
| 91315* | Sarscov2 vac bvl 10mcg/0.2ml | 10/12/2022 | |
| 93569 | Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective pulmonary arterial angiography, unilateral (List separately in addition to code for primary procedure) | 1/1/2023 | Max Units: 1 |
| 93573 | Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective pulmonary arterial angiography, bilateral (List separately in addition to code for primary procedure) | 1/1/2023 | Max Units: 1 |
| 93574 | Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective pulmonary venous angiography of each distinct pulmonary vein during cardiac catheterization (List separately in addition to code for primary procedure) | 1/1/2023 | Max Units: 4 |
| 93575 | Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective pulmonary angiography of major aortopulmonary collateral arteries (MAPCAs) arising off the aorta or its systemic branches, during cardiac catheterization for congenital heart defects, each distinct vessel (List separately in addition to code for primary procedure) | 1/1/2023 | Max Units: 1 |
| 99418 | Prolonged inpatient or observation evaluation and management service(s) time with or without direct patient contact beyond the required time of the primary service when the primary service level has been selected using total time, each 15 minutes of total time (List separately in addition to the code of the inpatient and observation Evaluation and Management service) | 1/1/2023 | Max Units: 4 |
| 0044A* | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (sarscov-2) (coronavirus disease [covid-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 ml dosage; booster dose | 10/19/2022 | |
| 0124A* | Adm sarscv2 bvl 30mcg/.3ml b | 8/31/2022 | |
| 0134A* | Adm sarscv2 bvl 50mcg/.5ml b | 8/31/2022 | |
| 0144A* | Adm srscv2 bvl 25mcg/.25ml b | 10/12/2022 | |
| 0154A* | Adm sarscv2 bvl 10mcg/.2ml b | 10/12/2022 | |
| C1826 | Generator, neurostimulator (implantable), includes closed feedback loop leads and all implantable components, with rechargeable battery and charging system | 1/1/2023 | Max Units: 1 |
| C1827 | Generator, neurostimulator (implantable), non-rechargeable, with implantable stimulation lead and external paired stimulation controller | 1/1/2023 | Max Units: 1 |

| | | | |
|--------------|--|----------|--------------|
| C7501 | Percutaneous breast biopsies using stereotactic guidance, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, all lesions unilateral and bilateral (for single lesion biopsy, use appropriate code) | 1/1/2023 | Max Units: 1 |
| C7502 | Percutaneous breast biopsies using magnetic resonance guidance, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, all lesions unilateral or bilateral (for single lesion biopsy, use appropriate code) | 1/1/2023 | Max Units: 1 |
| C7503 | Open biopsy or excision of deep cervical node(s) with intraoperative identification (eg, mapping) of sentinel lymph node(s) including injection of non-radioactive dye when performed | 1/1/2023 | Max Units: 1 |
| C7504 | Percutaneous vertebroplasties (bone biopsies included when performed), first cervicothoracic and any additional cervicothoracic or lumbosacral vertebral bodies, unilateral or bilateral injection, inclusive of all imaging guidance | 1/1/2023 | Max Units: 1 |
| C7505 | Percutaneous vertebroplasties (bone biopsies included when performed), first lumbosacral and any additional cervicothoracic or lumbosacral vertebral bodies, unilateral or bilateral injection, inclusive of all imaging guidance | 1/1/2023 | Max Units: 1 |
| C7506 | Arthrodesis, interphalangeal joints, with or without internal fixation | 1/1/2023 | Max Units: 1 |
| C7507 | Percutaneous vertebral augmentations, first thoracic and any additional thoracic or lumbar vertebral bodies, including cavity creations (fracture reductions and bone biopsies included when performed) using mechanical device (eg, kyphoplasty), unilateral or bilateral cannulations, inclusive of all imaging guidance | 1/1/2023 | Max Units: 1 |
| C7508 | Percutaneous vertebral augmentations, first lumbar and any additional thoracic or lumbar vertebral bodies, including cavity creations (fracture reductions and bone biopsies included when performed) using mechanical device (eg, kyphoplasty), unilateral or bilateral cannulations, inclusive of all imaging guidance | 1/1/2023 | Max Units: 1 |
| C7534 | Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(ies), unilateral, with atherectomy, includes angioplasty within the same vessel, when performed with intravascular ultrasound (initial noncoronary vessel) during diagnostic evaluation and/or therapeutic intervention, including radiological supervision and interpretation | 1/1/2023 | Max Units: 1 |
| C7535 | Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(ies), unilateral, with transluminal stent placement(s), includes angioplasty within the same vessel, when performed, with intravascular ultrasound (initial noncoronary vessel) during diagnostic evaluation and/or therapeutic intervention, including radiological supervision and interpretation | 1/1/2023 | Max Units: 1 |
| C7537 | Insertion of new or replacement of permanent pacemaker with atrial transvenous electrode(s), with insertion of pacing electrode, cardiac venous system, for left ventricular pacing, at time of insertion of implantable defibrillator or pacemaker pulse generator (eg, for upgrade to dual chamber system) | 1/1/2023 | Max Units: 1 |
| C7538 | Insertion of new or replacement of permanent pacemaker with ventricular transvenous electrode(s), with insertion of pacing electrode, cardiac venous system, for left ventricular pacing, at time of insertion of implantable defibrillator or pacemaker pulse generator (eg, for upgrade to dual chamber system) | 1/1/2023 | Max Units: 1 |

| | | | |
|--------------|--|----------|-------------------------------|
| C7539 | Insertion of new or replacement of permanent pacemaker with atrial and ventricular transvenous electrode(s), with insertion of pacing electrode, cardiac venous system, for left ventricular pacing, at time of insertion of implantable defibrillator or pacemaker pulse generator (eg, for upgrade to dual chamber system) | 1/1/2023 | Max Units: 1 |
| C7540 | Removal of permanent pacemaker pulse generator with replacement of pacemaker pulse generator, dual lead system, with insertion of pacing electrode, cardiac venous system, for left ventricular pacing, at time of insertion of implantable defibrillator or pacemaker pulse generator (eg, for upgrade to dual chamber system) | 1/1/2023 | Max Units: 1 |
| C7541 | Diagnostic endoscopic retrograde cholangiopancreatography (ercp), including collection of specimen(s) by brushing or washing, when performed, with endoscopic cannulation of papilla with direct visualization of pancreatic/common bile ducts(s) | 1/1/2023 | Max Units: 1 |
| C7542 | Endoscopic retrograde cholangiopancreatography (ercp) with biopsy, single or multiple, with endoscopic cannulation of papilla with direct visualization of pancreatic/common bile ducts(s) | 1/1/2023 | Max Units: 1 |
| C7543 | Endoscopic retrograde cholangiopancreatography (ercp) with sphincterotomy/papillotomy, with endoscopic cannulation of papilla with direct visualization of pancreatic/common bile ducts(s) | 1/1/2023 | Max Units: 1 |
| C7544 | Endoscopic retrograde cholangiopancreatography (ercp) with removal of calculi/debris from biliary/pancreatic duct(s), with endoscopic cannulation of papilla with direct visualization of pancreatic/common bile ducts(s) | 1/1/2023 | Max Units: 1 |
| C7555 | Thyroidectomy, total or complete with parathyroid autotransplantation | 1/1/2023 | Max Units: 1 |
| C9143 | Cocaine hydrochloride nasal solution (numbrino), 1 mg | 1/1/2023 | Min age: 18 Max Units: 160 |
| G0316 | Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99223, 99233, and 99236 for hospital inpatient or observation care evaluation and management services). (do not report G0316 on the same date of service as other prolonged services for evaluation and management 99358, 99359, 99418, 99415, 99416). (do not report G0316 for any time unit less than 15 minutes) | 1/1/2023 | Max Units: 2 |
| G0317 | Prolonged nursing facility evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99306, 99310 for nursing facility evaluation and management services). (do not report G0317 on the same date of service as other prolonged services for evaluation and management 99358, 99359, 99418). (do not report G0317 for any time unit less than 15 minutes) | 1/1/2023 | Max Units: 2 |

| | | | |
|--------------|---|----------|-------------------------------------|
| G0318 | Prolonged home or residence evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99345, 99350 for home or residence evaluation and management services). (do not report G0318 on the same date of service as other prolonged services for evaluation and management 99358, 99359, 99417). (do not report G0318 for any time unit less than 15 minutes) | 1/1/2023 | Max Units: 2 |
| G3002 | Chronic pain management and treatment, monthly bundle including, diagnosis; assessment and monitoring; administration of a validated pain rating scale or tool; the development, implementation, revision, and/or maintenance of a person-centered care plan that includes strengths, goals, clinical needs, and desired outcomes; overall treatment management; facilitation and coordination of any necessary behavioral health treatment; medication management; pain and health literacy counseling; any necessary chronic pain related crisis care; and ongoing communication and care coordination between relevant practitioners furnishing care, e.g. physical therapy and occupational therapy, complementary and integrative approaches, and community-based care, as appropriate. required initial face-to-face visit at least 30 minutes provided by a physician or other qualified health professional; first 30 minutes personally provided by physician or other qualified health care professional, per calendar month. (when using G3002, 30 minutes must be met or exceeded.) | 1/1/2023 | Max Units: 1 |
| G3003 | Each additional 15 minutes of chronic pain management and treatment by a physician or other qualified health care professional, per calendar month. (list separately in addition to code for G3002. when using G3003, 15 minutes must be met or exceeded.) | 1/1/2023 | Max Units: 1 |
| J0134 | Injection, acetaminophen (fresenius kabi) not therapeutically equivalent to j0131, 10 mg | 1/1/2023 | Max Units: 400 |
| J0136 | Injection, acetaminophen (b braun) not therapeutically equivalent to J0131, 10 mg | 1/1/2023 | Max Units: 400 |
| J0283 | Injection, amiodarone hydrochloride (nexterone), 30 mg | 1/1/2023 | Max Units: 70 |
| J0611 | Injection, calcium gluconate (wg critical care), per 10 mL | 1/1/2023 | Max Units: 15 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to J0690, 500 mg | 1/1/2023 | Max Units: 16 |
| J0701 | Injection, cefepime hydrochloride (baxter), not therapeutically equivalent to maxipime, 500 mg | 1/1/2023 | Max Units: 12 |
| J0703 | Injection, cefepime hydrochloride (b braun), not therapeutically equivalent to maxipime, 500 mg | 1/1/2023 | Max Units: 12 |
| J0877 | Injection, daptomycin (hospira), not therapeutically equivalent to J0878, 1 mg | 1/1/2023 | Min Age: 1 (one) Max Units: 1500 |
| J0891 | Injection, argatroban (accord), not therapeutically equivalent to J0883, 1 mg (for non-esrd use) | 1/1/2023 | Max Units: 1250 |
| J0892 | Injection, argatroban (accord), not therapeutically equivalent to J0884, 1 mg (for esrd on dialysis) | 1/1/2023 | Max Units: 1250 |
| J0893 | Injection, decitabine (sun pharma) not therapeutically equivalent to J0894, 1 mg | 1/1/2023 | Min age: 18 Max Units: 100 |
| J0898 | Injection, argatroban (auromedics), not therapeutically equivalent to J0883, 1 mg (for non-esrd use) | 1/1/2023 | Max Units: 1250 |
| J0899 | Injection, argatroban (auromedics), not therapeutically equivalent to J0884, 1 mg (for esrd on dialysis) | 1/1/2023 | Max Units: 1250 |

| | | | |
|--------------|---|----------|--|
| J1456 | Injection, fosaprepitant (teva), not therapeutically equivalent to J1453, 1 mg | 1/1/2023 | Max Units: 150 |
| J1574 | Injection, ganciclovir sodium (exela) not therapeutically equivalent to J1570, 500 mg | 1/1/2023 | Max Units: 4 |
| J1611 | Injection, glucagon hydrochloride (fresenius kabi), not therapeutically equivalent to J1610, per 1 mg | 1/1/2023 | Max Units: 3 |
| J1643 | Injection, heparin sodium (pfizer), not therapeutically equivalent to J1644, per 1000 units | 1/1/2023 | Max Units: 50 |
| J2021 | Injection, linezolid (hospira) not therapeutically equivalent to J2020, 200 mg | 1/1/2023 | Max Units: 6 |
| J2184 | Injection, meropenem (b. braun) not therapeutically equivalent to J2185, 100 mg | 1/1/2023 | Max Units: 60 |
| J2247 | Injection, micafungin sodium (par pharm) not therapeutically equivalent to J2248, 1 mg | 1/1/2023 | Max Units: 300 |
| J2251 | Injection, midazolam hydrochloride (wg critical care) not therapeutically equivalent to J2250, per 1 mg | 1/1/2023 | Max Units: 30 |
| J2272 | Injection, morphine sulfate (fresenius kabi) not therapeutically equivalent to J2270, up to 10 mg | 1/1/2023 | Max Units: 15 |
| J2281 | Injection, moxifloxacin (fresenius kabi) not therapeutically equivalent to J2280, 100 mg | 1/1/2023 | Max Units: 8 |
| J2311 | Injection, naloxone hydrochloride (zimhi), 1 mg | 1/1/2023 | Max Units: 10 |
| J2401 | Injection, chlorprocaine hydrochloride, per 30 ml | 1/1/2023 | No restrictions No Max Units available |
| J2402 | Injection, chlorprocaine hydrochloride (clorotekal), per 1 mg | 1/1/2023 | No restrictions No Max Units available |
| J3244 | Injection, tigecycline (accord) not therapeutically equivalent to J3243, 1 mg | 1/1/2023 | Max Units: 200 |
| J3371 | Injection, vancomycin hcl (mylan) not therapeutically equivalent to J3370, 500 mg | 1/1/2023 | Max Units: 12 |
| J3372 | Injection, vancomycin hcl (xellia) not therapeutically equivalent to J3370, 500 mg | 1/1/2023 | Max Units: 12 |
| J9046 | Injection, bortezomib, (dr. reddy's), not therapeutically equivalent to J9041, 0.1 mg | 1/1/2023 | Min age: 18 Max Units: 35 |
| J9048 | Injection, bortezomib (fresenius kabi), not therapeutically equivalent to J9041, 0.1 mg | 1/1/2023 | Min age: 18 Max Units: 35 |
| J9049 | Injection, bortezomib (hospira), not therapeutically equivalent to J9041, 0.1 mg | 1/1/2023 | Min age: 18 Max Units: 35 |
| J9314 | Injection, pemetrexed (teva) not therapeutically equivalent to J9305, 10 mg | 1/1/2023 | Max Units: 150 |

*Covid Related Code

[Back to top](#)

Table 2 - CDT©

| Dental Code | Description | Effective Date |
|--------------------|---|-----------------------|
| D0372 | Intraoral tomosynthesis - comprehensive series of radiographic images | 1/1/2023 |
| D0373 | Intraoral tomosynthesis - bitewing radiographic image | 1/1/2023 |
| D0374 | Intraoral tomosynthesis - periapical radiographic image | 1/1/2023 |
| D0387 | Intraoral tomosynthesis - comprehensive series of radiographic images - image capture only | 1/1/2023 |
| D0388 | Intraoral tomosynthesis - bitewing radiographic image - image capture only | 1/1/2023 |
| D0389 | Intraoral tomosynthesis - periapical radiographic image - image capture only | 1/1/2023 |
| D0801 | 3d dental surface scan - direct | 1/1/2023 |
| D0802 | 3d dental surface scan - indirect | 1/1/2023 |
| D0803 | 3d facial surface scan - direct | 1/1/2023 |
| D0804 | 3d facial surface scan - indirect | 1/1/2023 |
| D1781 | Vaccine administration - human papillomavirus - dose 1 | 1/1/2023 |
| D1782 | Vaccine administration - human papillomavirus - dose 2 | 1/1/2023 |
| D1783 | Vaccine administration - human papillomavirus - dose 3 | 1/1/2023 |
| D4286 | Removal of non-resorbable barrier | 1/1/2023 |
| D6105 | Removal of implant body not requiring bone removal or flap elevation | 1/1/2023 |
| D6106 | Guided tissue regeneration - resorbable barrier, per implant | 1/1/2023 |
| D6107 | Guided tissue regeneration - non-resorbable barrier, per implant | 1/1/2023 |
| D6197 | Replacement of restorative material used to close an access opening of a screw-retained implant supported prosthesis, per implant | 1/1/2023 |
| D7509 | Marsupialization of odontogenic cyst | 1/1/2023 |
| D7956 | Guided tissue regeneration, edentulous area - resorbable barrier, per site | 1/1/2023 |
| D7957 | Guided tissue regeneration, edentulous area - non-resorbable barrier, per site | 1/1/2023 |
| D9953 | Reline custom sleep apnea appliance (indirect) | 1/1/2023 |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | 1/1/2023 |

[Back to top](#)

Table 3 – ICD-10-CM Codes

| ICD-10-CM Code | Description | Effective Date | Special Billing Information |
|-----------------------|--|-----------------------|------------------------------------|
| T74.A1XA | Adult financial abuse, confirmed, initial encounter | 4/1/2023 | Min age: 15; Both Sexes |
| T74.A1XD | Adult financial abuse, confirmed, subsequent encounter | 4/1/2023 | Min age: 15; Both Sexes |
| T74.A1XS | Adult financial abuse, confirmed, sequela | 4/1/2023 | Min age: 15; Both Sexes |
| T74.A2XA | Child financial abuse, confirmed, initial encounter | 4/1/2023 | Max age: 18; Both Sexes |
| T74.A2XD | Child financial abuse, confirmed, subsequent encounter | 4/1/2023 | Max age: 18; Both Sexes |
| T74.A2XS | Child financial abuse, confirmed, sequela | 4/1/2023 | Max age: 18; Both Sexes |
| T76.A1XA | Adult financial abuse, suspected, initial encounter | 4/1/2023 | Min age: 15; Both Sexes |
| T76.A1XD | Adult financial abuse, suspected, subsequent encounter | 4/1/2023 | Min age: 15; Both Sexes |
| T76.A1XS | Adult financial abuse, suspected, sequela | 4/1/2023 | Min age: 15; Both Sexes |
| T76.A2XA | Child financial abuse, suspected, initial encounter | 4/1/2023 | Max age: 18; Both Sexes |
| T76.A2XD | Child financial abuse, suspected, subsequent encounter | 4/1/2023 | Max age: 18; Both Sexes |
| T76.A2XS | Child financial abuse, suspected, sequela | 4/1/2023 | Max age: 18; Both Sexes |
| Y07.010 | Husband, current, perpetrator of maltreatment and neglect | 4/1/2023 | Min age: 15; Male Only |
| Y07.011 | Husband, former, perpetrator of maltreatment and neglect | 4/1/2023 | Min age: 15; Male Only |
| Y07.020 | Wife, current, perpetrator of maltreatment and neglect | 4/1/2023 | Female Only |
| Y07.021 | Wife, former, perpetrator of maltreatment and neglect | 4/1/2023 | Female Only |
| Y07.030 | Male partner, current, perpetrator of maltreatment and neglect | 4/1/2023 | Both Sexes |
| Y07.031 | Male partner, former, perpetrator of maltreatment and neglect | 4/1/2023 | Both Sexes |

| | | | |
|----------------|--|----------|--------------------------------|
| Y07.040 | Female partner, current, perpetrator of maltreatment and neglect | 4/1/2023 | Both Sexes |
| Y07.041 | Female partner, former, perpetrator of maltreatment and neglect | 4/1/2023 | Both Sexes |
| Y07.050 | Non-binary partner, current, perpetrator of maltreatment and neglect | 4/1/2023 | Both Sexes |
| Y07.051 | Non-binary partner, former, perpetrator of maltreatment and neglect | 4/1/2023 | Both Sexes |
| Y07.44 | Child, perpetrator of maltreatment and neglect | 4/1/2023 | Both Sexes |
| Y07.45 | Grandchild, perpetrator of maltreatment and neglect | 4/1/2023 | Both Sexes |
| Y07.46 | Grandparent, perpetrator of maltreatment and neglect | 4/1/2023 | Both Sexes |
| Y07.47 | Parental sibling, perpetrator of maltreatment and neglect | 4/1/2023 | Both Sexes |
| Y07.54 | Acquaintance or friend, perpetrator of maltreatment and neglect | 4/1/2023 | Both Sexes |
| Z58.81 | Basic services unavailable in physical environment | 4/1/2023 | Both Sexes |
| Z58.89 | Other problems related to physical environment | 4/1/2023 | Both Sexes |
| Z62.814 | Personal history of child financial abuse | 4/1/2023 | Requires Claim Review |
| Z62.815 | Personal history of intimate partner abuse in childhood | 4/1/2023 | Requires Claim Review |
| Z91.413 | Personal history of adult financial abuse | 4/1/2023 | Min age: 15; non-specific code |
| Z91.414 | Personal history of adult intimate partner abuse | 4/1/2023 | Min age: 15; non-specific code |

[Back to top](#)

Table 4 – ICD-10-PCS Codes

| ICD-10-PCS Code | Description | Effective Date |
|------------------------|---|-----------------------|
| 02LW0DJ | Occlusion of Thoracic Aorta, Descending with Intraluminal Device, Temporary, Open Approach | 4/1/2023 |
| 04L00DJ | Occlusion of Abdominal Aorta with Intraluminal Device, Temporary, Open Approach | 4/1/2023 |
| 0P530Z3 | Destruction of Cervical Vertebra using Laser Interstitial Thermal Therapy, Open Approach | 4/1/2023 |
| 0P533Z3 | Destruction of Cervical Vertebra using Laser Interstitial Thermal Therapy, Percutaneous Approach | 4/1/2023 |
| 0P534Z3 | Destruction of Cervical Vertebra using Laser Interstitial Thermal Therapy, Percutaneous Endoscopic Approach | 4/1/2023 |
| 0P540Z3 | Destruction of Thoracic Vertebra using Laser Interstitial Thermal Therapy, Open Approach | 4/1/2023 |
| 0P543Z3 | Destruction of Thoracic Vertebra using Laser Interstitial Thermal Therapy, Percutaneous Approach | 4/1/2023 |
| 0P544Z3 | Destruction of Thoracic Vertebra using Laser Interstitial Thermal Therapy, Percutaneous Endoscopic Approach | 4/1/2023 |
| 0Q500Z3 | Destruction of Lumbar Vertebra using Laser Interstitial Thermal Therapy, Open Approach | 4/1/2023 |

| | | |
|----------------|---|----------|
| 0Q503Z3 | Destruction of Lumbar Vertebra using Laser Interstitial Thermal Therapy, Percutaneous Approach | 4/1/2023 |
| 0Q504Z3 | Destruction of Lumbar Vertebra using Laser Interstitial Thermal Therapy, Percutaneous Endoscopic Approach | 4/1/2023 |
| 0Q510Z3 | Destruction of Sacrum using Laser Interstitial Thermal Therapy, Open Approach | 4/1/2023 |
| 0Q513Z3 | Destruction of Sacrum using Laser Interstitial Thermal Therapy, Percutaneous Approach | 4/1/2023 |
| 0Q514Z3 | Destruction of Sacrum using Laser Interstitial Thermal Therapy, Percutaneous Endoscopic Approach | 4/1/2023 |
| 302A3H0 | Transfusion of Autologous Whole Blood into Bone Marrow, Percutaneous Approach | 4/1/2023 |
| 302A3H1 | Transfusion of Nonautologous Whole Blood into Bone Marrow, Percutaneous Approach | 4/1/2023 |
| 302A3J0 | Transfusion of Autologous Serum Albumin into Bone Marrow, Percutaneous Approach | 4/1/2023 |
| 302A3J1 | Transfusion of Nonautologous Serum Albumin into Bone Marrow, Percutaneous Approach | 4/1/2023 |
| 302A3K0 | Transfusion of Autologous Frozen Plasma into Bone Marrow, Percutaneous Approach | 4/1/2023 |
| 302A3K1 | Transfusion of Nonautologous Frozen Plasma into Bone Marrow, Percutaneous Approach | 4/1/2023 |
| 302A3L0 | Transfusion of Autologous Fresh Plasma into Bone Marrow, Percutaneous Approach | 4/1/2023 |
| 302A3L1 | Transfusion of Nonautologous Fresh Plasma into Bone Marrow, Percutaneous Approach | 4/1/2023 |
| 302A3N0 | Transfusion of Autologous Red Blood Cells into Bone Marrow, Percutaneous Approach | 4/1/2023 |
| 302A3N1 | Transfusion of Nonautologous Red Blood Cells into Bone Marrow, Percutaneous Approach | 4/1/2023 |
| 302A3P0 | Transfusion of Autologous Frozen Red Cells into Bone Marrow, Percutaneous Approach | 4/1/2023 |
| 302A3P1 | Transfusion of Nonautologous Frozen Red Cells into Bone Marrow, Percutaneous Approach | 4/1/2023 |
| 302A3R0 | Transfusion of Autologous Platelets into Bone Marrow, Percutaneous Approach | 4/1/2023 |
| 302A3R1 | Transfusion of Nonautologous Platelets into Bone Marrow, Percutaneous Approach | 4/1/2023 |
| XW013G6 | Introduction of REGN-COV2 Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 | 4/1/2023 |
| XW0DXK8 | Introduction of Sabizabulin into Mouth and Pharynx, External Approach, New Technology Group 8 | 4/1/2023 |
| XW0G7K8 | Introduction of Sabizabulin into Upper GI, Via Natural or Artificial Opening, New Technology Group 8 | 4/1/2023 |
| XW0H7K8 | Introduction of Sabizabulin into Lower GI, Via Natural or Artificial Opening, New Technology Group 8 | 4/1/2023 |
| XW133J8 | Transfusion of Exagamglogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 8 | 4/1/2023 |
| XW143J8 | Transfusion of Exagamglogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8 | 4/1/2023 |

[Back to top](#)

Table 5 - Modifiers

| Modifier | Desc | Effective Date |
|-----------------|--------------------------------------|-----------------------|
| N1 | Group 1 oxygen coverage criteria met | 1/1/2023 |
| N2 | Group 2 oxygen coverage criteria met | 1/1/2023 |
| N3 | Group 3 oxygen coverage criteria met | 1/1/2023 |

[Back to top](#)

Table 6 – Codes that require a Pre-Pay or Post-Pay claim review.

| Code | Desc | Effective Date | Special Billing Information |
|--------------|--|----------------|-----------------------------|
| 22860 | Total disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare interspace (other than for decompression); second interspace, lumbar (List separately in addition to code for primary procedure) | 1/1/2023 | PA Required |
| 69728 | Removal, entire osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, outside the mastoid and involving a bony defect greater than or equal to 100 sq mm surface area of bone deep to the outer cranial cortex | 1/1/2023 | PA Required Max Units: 1 |
| 69729 | Implantation, osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, outside of the mastoid and resulting in removal of greater than or equal to 100 sq mm surface area of bone deep to the outer cranial cortex | 1/1/2023 | PA Required Max Units: 1 |
| 69730 | Replacement of cochlear stimulating system outside mastoid bone of skull with magnetic attachment to external speech processor | 1/1/2023 | PA Required Max Units: 1 |
| 0742T | Absolute quantitation of myocardial blood flow (AQMBF), single-photon emission computed tomography (SPECT), with exercise or pharmacologic stress, and at rest, when performed (List separately in addition to code for primary procedure) | 1/1/2023 | PA Required Max Units: 1 |
| 0743T | Bone strength and fracture risk using finite element analysis of functional data and bone-mineral density, with concurrent vertebral fracture assessment, utilizing data from a computed tomography scan, retrieval and transmission of the scan data, measurement of bone strength and bone mineral density and classification of any vertebral fractures, with overall fracture risk assessment, interpretation and report | 1/1/2023 | PA Required Max Units: 1 |
| 0749T | Bone strength and fracture-risk assessment using digital X-ray radiogrammetry-bone mineral density (DXR-BMD) analysis of bone mineral density (BMD) utilizing data from a digital X ray, retrieval and transmission of digital X ray data, assessment of bone strength and fracture-risk and BMD, interpretation and report; | 1/1/2023 | PA Required |
| 0750T | Bone strength and fracture-risk assessment using digital X-ray radiogrammetry-bone mineral density (DXR-BMD) analysis of bone mineral density (BMD) utilizing data from a digital X ray, retrieval and transmission of digital X ray data, assessment of bone strength and fracture-risk and BMD, interpretation and report; with single-view digital X-ray examination of the hand taken for the purpose of DXR-BMD | 1/1/2023 | PA Required |
| 0751T | Digitization of glass microscope slides for level II, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure) | 1/1/2023 | PA Required |
| 0752T | Digitization of glass microscope slides for level III, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure) | 1/1/2023 | PA Required |
| 0753T | Digitization of glass microscope slides for level IV, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure) | 1/1/2023 | PA Required |
| 0754T | Digitization of glass microscope slides for level V, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure) | 1/1/2023 | PA Required |

| | | | |
|--------------|---|----------|---|
| 0755T | Digitization of glass microscope slide for level VI, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure) | 1/1/2023 | PA Required |
| 0756T | Digitization of glass microscope slides for special stain, including interpretation and report, group I, for microorganisms (eg, acid fast, methenamine silver) (List separately in addition to code for primary procedure) | 1/1/2023 | PA Required |
| 0757T | Digitization of glass microscope slides for special stain, including interpretation and report, group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry (List separately in addition to code for primary procedure) | 1/1/2023 | PA Required |
| 0758T | Digitization of glass microscope slides for special stain, including interpretation and report, histochemical stain on frozen tissue block (List separately in addition to code for primary procedure) | 1/1/2023 | PA Required |
| 0759T | Digitization of glass microscope slides for special stain, including interpretation and report, group III, for enzyme constituents (List separately in addition to code for primary procedure) | 1/1/2023 | PA Required |
| 0760T | Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per specimen, initial single antibody stain procedure (List separately in addition to code for primary procedure) | 1/1/2023 | PA Required |
| 0761T | Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per specimen, each additional single antibody stain procedure (List separately in addition to code for primary procedure) | 1/1/2023 | PA Required |
| 0762T | Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per specimen, each multiplex antibody stain procedure (List separately in addition to code for primary procedure) | 1/1/2023 | PA Required |
| 0763T | Digitization of glass microscope slides for morphometric analysis, tumor immunohistochemistry (eg, Her-2/neu, estrogen receptor/progesterone receptor), quantitative or semiquantitative, per specimen, each single antibody stain procedure, manual (List separately in addition to code for primary procedure) | 1/1/2023 | PA Required |
| 0764T | Assistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (eg, low-ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy); related to concurrently performed electrocardiogram (List separately in addition to code for primary procedure) | 1/1/2023 | PA Required Max Units: 1 |
| 0765T | Assistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (eg, low-ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy); related to previously performed electrocardiogram | 1/1/2023 | PA Required Max Units: 1 |
| A4239 | Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service | 1/1/2023 | PA Required Max Units: 1 |
| E2103 | Non-adjunctive, non-implanted continuous glucose monitor or receiver | 1/1/2023 | PA Required Max Units: 1 |
| J0225 | Injection, vutrisiran, 1 mg | 1/1/2023 | PA Required Max Units: 25 |
| J1954 | Injection, leuprolide acetate for depot suspension (lutrate), 7.5 mg | 1/1/2023 | Suspend for Claim Review Max Units: 6 |

| | | | |
|--------------|--|----------|---|
| J2327 | Injection, risankizumab-rzaa, intravenous, 1 mg | 1/1/2023 | PA Required Max Units: 600 |
| J9393 | Injection, fulvestrant (teva) not therapeutically equivalent to J9395, 25 mg | 1/1/2023 | Suspend for Claim Review Max Units: 20 |
| J9394 | Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to J9395, 25 mg | 1/1/2023 | Suspend for Claim Review Max Units: 20 |
| Q5126 | Injection, bevacizumab-maly, biosimilar, (alymys), 10 mg | 1/1/2023 | PA Required Min age: 18 Max Units: 270 |

[Back to top](#)

Table 7 – Non-covered codes

| Code | Description |
|--------------|--|
| 30469 | Repair of nasal valve collapse with low energy, temperature-controlled (i.e., radiofrequency) subcutaneous/submucosal remodeling |
| 36836 | Percutaneous arteriovenous fistula creation, upper extremity, single access of both the peripheral artery and peripheral vein, including fistula maturation procedures (eg, transluminal balloon angioplasty, coil embolization) when performed, including all vascular access, imaging guidance and radiologic supervision and interpretation |
| 36837 | Percutaneous arteriovenous fistula creation, upper extremity, separate access sites of the peripheral artery and peripheral vein, including fistula maturation procedures (eg, transluminal balloon angioplasty, coil embolization) when performed, including all vascular access, imaging guidance and radiologic supervision and interpretation |
| 43290 | Esophagogastroduodenoscopy, flexible, transoral; with deployment of intragastric bariatric balloon |
| 43291 | Esophagogastroduodenoscopy, flexible, transoral; with removal of intragastric bariatric balloon(s) |
| 81418 | Genomic sequence analysis panel of at least 6 genes associated with drug metabolism |
| 81441 | Inherited bone marrow failure syndromes (IBMFS) (eg, Fanconi anemia, dyskeratosis congenita, Diamond-Blackfan anemia, Shwachman-Diamond syndrome, GATA2 deficiency syndrome, congenital amegakaryocytic thrombocytopenia) sequence analysis panel, must include sequencing of at least 30 genes, including BRCA2, BRIPI, DKCI, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, GATA1, GATA2, MPL, NHP2, NOPI0, PALB2, RAD51C, RPL11, RPL35A, RPL5, RPS10, RPS19, RPS24, RPS26, RPS7, SBDS, TERT, and TINF2 |
| 81449 | Targeted genomic sequence analysis panel, solid organ neoplasm, 5-50 genes (eg, ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, MET, NRAS, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, if performed; RNA analysis |

| | |
|--------------|---|
| 81451 | Targeted genomic sequence analysis panel, hematolymphoid neoplasm or disorder, 5-50 genes (eg, BRAF, CEBPA, DNMT3A, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MLL, NOTCH1, NPM1, NRAS), interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA analysis |
| 81456 | Targeted genomic sequence analysis panel, solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes (eg, ALK, BRAF, CDKN2A, CEBPA, DNMT3A, EGFR, ERBB2, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MET, MLL, NOTCH1, NPM1, NRAS, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA analysis |
| 90678 | Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use |
| 91321 | Coronavirus vaccine 22 |
| 91322 | Coronavirus vaccine 23 |
| 91323 | Coronavirus vaccine 24 |
| 91324 | Coronavirus vaccine 25 |
| 91325 | Coronavirus vaccine 26 |
| 92066 | Orthoptic training; under supervision of a physician or other qualified health care professional |
| 95919 | Quantitative pupillometry with physician or other qualified health care professional interpretation and report, unilateral or bilateral |
| 98978 | Remote therapeutic monitoring (eg, therapy adherence, therapy response); device(s) supply with scheduled (eg, daily) recording(s) and/or programmed alert(s) transmission to monitor cognitive behavioral therapy, each 30 days |
| 0210A | Administration of coronavirus vaccine 22, reserved |
| 0211A | Administration of coronavirus vaccine 22, reserved |
| 0212A | Administration of coronavirus vaccine 22, reserved |
| 0213A | Administration of coronavirus vaccine 22, reserved |
| 0214A | Administration of coronavirus vaccine 22, reserved |
| 0215A | Administration of coronavirus vaccine 22, reserved |
| 0216A | Administration of coronavirus vaccine 22, reserved |
| 0217A | Administration of coronavirus vaccine 22, reserved |
| 0218A | Administration of coronavirus vaccine 22, reserved |
| 0219A | Administration of coronavirus vaccine 22, reserved |
| 0220A | Administration of coronavirus vaccine 23, reserved |
| 0221A | Administration of coronavirus vaccine 23, reserved |
| 0222A | Administration of coronavirus vaccine 23, reserved |
| 0223A | Administration of coronavirus vaccine 23, reserved |
| 0224A | Administration of coronavirus vaccine 23, reserved |
| 0225A | Administration of coronavirus vaccine 23, reserved |
| 0226A | Administration of coronavirus vaccine 23, reserved |
| 0227A | Administration of coronavirus vaccine 23, reserved |

| | |
|--------------|---|
| 0228A | Administration of coronavirus vaccine 23, reserved |
| 0229A | Administration of coronavirus vaccine 23, reserved |
| 0230A | Administration of coronavirus vaccine 24, reserved |
| 0231A | Administration of coronavirus vaccine 24, reserved |
| 0232A | Administration of coronavirus vaccine 24, reserved |
| 0233A | Administration of coronavirus vaccine 24, reserved |
| 0234A | Administration of coronavirus vaccine 24, reserved |
| 0235A | Administration of coronavirus vaccine 24, reserved |
| 0236A | Administration of coronavirus vaccine 24, reserved |
| 0237A | Administration of coronavirus vaccine 24, reserved |
| 0238A | Administration of coronavirus vaccine 24, reserved |
| 0239A | Administration of coronavirus vaccine 24, reserved |
| 0240A | Administration of coronavirus vaccine 24, reserved |
| 0241A | Administration of coronavirus vaccine 25, reserved |
| 0242A | Administration of coronavirus vaccine 25, reserved |
| 0243A | Administration of coronavirus vaccine 25, reserved |
| 0244A | Administration of coronavirus vaccine 25, reserved |
| 0245A | Administration of coronavirus vaccine 25, reserved |
| 0246A | Administration of coronavirus vaccine 25, reserved |
| 0247A | Administration of coronavirus vaccine 25, reserved |
| 0248A | Administration of coronavirus vaccine 25, reserved |
| 0249A | Administration of coronavirus vaccine 25, reserved |
| 0250A | Administration of coronavirus vaccine 26, reserved |
| 0251A | Administration of coronavirus vaccine 26, reserved |
| 0252A | Administration of coronavirus vaccine 26, reserved |
| 0253A | Administration of coronavirus vaccine 26, reserved |
| 0254A | Administration of coronavirus vaccine 26, reserved |
| 0255A | Administration of coronavirus vaccine 26, reserved |
| 0256A | Administration of coronavirus vaccine 26, reserved |
| 0257A | Administration of coronavirus vaccine 26, reserved |
| 0258A | Administration of coronavirus vaccine 26, reserved |
| 0259A | Administration of coronavirus vaccine 26, reserved |
| 0355U | APOLI (apolipoprotein LI) (eg, chronic kidney disease), risk variants (G1, G2) |
| 0356U | Oncology (oropharyngeal), evaluation of 17 DNA biomarkers using droplet digital PCR (ddPCR), cell-free DNA, algorithm reported as a prognostic risk score for cancer recurrence |

| | |
|--------------|--|
| 0357U | Oncology (melanoma), artificial intelligence (AI)-enabled quantitative mass spectrometry analysis of 142 unique pairs of glycopeptide and product fragments, plasma, prognostic, and predictive algorithm reported as likely, unlikely, or uncertain benefit from immunotherapy agents |
| 0358U | Neurology (mild cognitive impairment), analysis of B-amyloid 1-42 and 1-40, chemiluminescence enzyme immunoassay, cerebral spinal fluid, reported as positive, likely positive, or negative |
| 0359U | Oncology (prostate cancer), analysis of all prostate-specific antigen (PSA) structural isoforms by phase separation and immunoassay, plasma, algorithm reports risk of cancer |
| 0360U | Oncology (lung), enzyme-linked immunosorbent assay (ELISA) of 7 autoantibodies (p53, NY-ESO-1, CAGE, GBU4-5, SOX2, MAGE A4, and HuD), plasma, algorithm reported as a categorical result for risk of malignancy |
| 0361U | Neurofilament light chain, digital immunoassay, plasma, quantitative |
| 0362U | Oncology (papillary thyroid cancer), gene-expression profiling via targeted hybrid capture–enrichment RNA sequencing of 82 content genes and 10 housekeeping genes, formalin-fixed paraffin embedded (FFPE) tissue, algorithm reported as one of three molecular subtypes |
| 0363U | Oncology (urothelial), mRNA, gene-expression profiling by real-time quantitative PCR of 5 genes (MDK, HOXA13, CDC2 [CDK1], IGFBP5, and CXCR2), utilizing urine, algorithm incorporates age, sex, smoking history, and macrohematuria frequency, reported as a risk score for having urothelial carcinoma |
| 0738T | Treatment planning for magnetic field induction ablation of malignant prostate tissue, using data from previously performed magnetic resonance imaging (MRI) examination |
| 0739T | Ablation of malignant prostate tissue by magnetic field induction, including all intraprocedural, transperineal needle/catheter placement for nanoparticle installation and intraprocedural temperature monitoring, thermal dosimetry, bladder irrigation, and magnetic field nanoparticle activation |
| 0740T | Remote autonomous algorithm-based recommendation system for insulin dose calculation and titration; initial set-up and patient education |
| 0741T | Remote autonomous algorithm-based recommendation system for insulin dose calculation and titration; provision of software, data collection, transmission, and storage, each 30 days |
| 0744T | Insertion of bioprosthetic valve, open, femoral vein, including duplex ultrasound imaging guidance, when performed, including autogenous or nonautogenous patch graft (eg, polyester, ePTFE, bovine pericardium), when performed |
| 0745T | Cardiac focal ablation utilizing radiation therapy for arrhythmia; noninvasive arrhythmia localization and mapping of arrhythmia site (nidus), derived from anatomical image data (eg, CT, MRI, or myocardial perfusion scan) and electrical data (eg, 12-lead ECG data), and identification of areas of avoidance |
| 0746T | Cardiac focal ablation utilizing radiation therapy for arrhythmia; conversion of arrhythmia localization and mapping of arrhythmia site (nidus) into a multidimensional radiation treatment plan |
| 0747T | Cardiac focal ablation utilizing radiation therapy for arrhythmia; delivery of radiation therapy, arrhythmia |
| 0748T | Injections of stem cell product into perianal perifistular soft tissue, including fistula preparation (eg, removal of setons, fistula curettage, closure of internal openings) |
| 0766T | Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, initial treatment, with identification and marking of the treatment location, including noninvasive electroneurographic localization (nerve conduction localization), when performed; first nerve |

| | |
|--------------|---|
| 0767T | Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, initial treatment, with identification and marking of the treatment location, including noninvasive electroneurographic localization (nerve conduction localization), when performed; each additional nerve (List separately in addition to code for primary procedure) |
| 0768T | Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, subsequent treatment, including noninvasive electroneurographic localization (nerve conduction localization), when performed; first nerve |
| 0769T | Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, subsequent treatment, including noninvasive electroneurographic localization (nerve conduction localization), when performed; each additional nerve (List separately in addition to code for primary procedure) |
| 0770T | Virtual reality technology to assist therapy (List separately in addition to code for primary procedure) |
| 0771T | Virtual reality (VR) procedural dissociation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports, requiring the presence of an independent, trained observer to assist in the monitoring of the patient's level of dissociation or consciousness and physiological status; initial 15 minutes of intraservice time, patient aged 5 years or older |
| 0772T | Virtual reality (VR) procedural dissociation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports, requiring the presence of an independent, trained observer to assist in the monitoring of the patient's level of dissociation or consciousness and physiological status; each additional 15 minutes intraservice time (List separately in addition to code for primary service) |
| 0773T | Virtual reality (VR) procedural dissociation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports; initial 15 minutes of intraservice time, patient aged 5 years or older |
| 0774T | Virtual reality (VR) procedural dissociation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports; each additional 15 minutes intraservice time (List separately in addition to code for primary service) |
| 0775T | Arthrodesis, sacroiliac joint, percutaneous, with image guidance, includes placement of intra-articular implant(s) (eg, bone allograft[s], synthetic device[s]) |
| 0776T | Therapeutic induction of intra-brain hypothermia, including placement of a mechanical temperature-controlled cooling device to the neck over carotids and head, including monitoring (eg, vital signs and sport concussion assessment tool 5 [SCAT5]), 30 minutes of treatment |
| 0777T | Real-time pressure-sensing epidural guidance system (List separately in addition to code for primary procedure) |
| 0778T | Surface mechanomyography (sMMG) with concurrent application of inertial measurement unit (IMU) sensors for measurement of multi-joint range of motion, posture, gait, and muscle function |
| 0779T | Gastrointestinal myoelectrical activity study, stomach through colon, with interpretation and report |
| 0780T | Instillation of fecal microbiota suspension via rectal enema into lower gastrointestinal tract |
| 0781T | Bronchoscopy, rigid or flexible, with insertion of esophageal protection device and circumferential radiofrequency destruction of the pulmonary nerves, including fluoroscopic guidance when performed; bilateral mainstem bronchi |
| 0782T | Bronchoscopy, rigid or flexible, with insertion of esophageal protection device and circumferential radiofrequency destruction of the pulmonary nerves, including fluoroscopic guidance when performed; unilateral mainstem bronchus |

| | |
|--------------|--|
| 0783T | Transcutaneous auricular neurostimulation, set-up, calibration, and patient education on use of equipment |
| C1747 | Endoscope, single-use (i.e. disposable), urinary tract, imaging/illumination device (insertable) |
| C7500 | Debridement, bone including epidermis, dermis, subcutaneous tissue, muscle and/or fascia, if performed, first 20 sq cm or less with manual preparation and insertion of deep (eg. subfacial) drug-delivery device(s) |
| C7509 | Bronchoscopy, rigid or flexible, diagnostic with cell washing(s) when performed, with computer-assisted image-guided navigation, including fluoroscopic guidance when performed |
| C7510 | Bronchoscopy, rigid or flexible, with bronchial alveolar lavage(s), with computer-assisted image-guided navigation, including fluoroscopic guidance when performed |
| C7511 | Bronchoscopy, rigid or flexible, with single or multiple bronchial or endobronchial biopsy(ies), single or multiple sites, with computer-assisted image-guided navigation, including fluoroscopic guidance when performed |
| C7512 | Bronchoscopy, rigid or flexible, with single or multiple bronchial or endobronchial biopsy(ies), single or multiple sites, with transendoscopic endobronchial ultrasound (ebus) during bronchoscopic diagnostic or therapeutic intervention(s) for peripheral lesion(s), including fluoroscopic guidance when performed |
| C7513 | Dialysis circuit, introduction of needle(s) and/or catheter(s), with diagnostic angiography of the dialysis circuit, including all direct puncture(s) and catheter placement(s), injection(s) of contrast, all necessary imaging from the arterial anastomosis and adjacent artery through entire venous outflow including the inferior or superior vena cava, fluoroscopic guidance, with transluminal balloon angioplasty of central dialysis segment, performed through dialysis circuit, including all required imaging, radiological supervision and interpretation, image documentation and report |
| C7514 | Dialysis circuit, introduction of needle(s) and/or catheter(s), with diagnostic angiography of the dialysis circuit, including all direct puncture(s) and catheter placement(s), injection(s) of contrast, all necessary imaging from the arterial anastomosis and adjacent artery through entire venous outflow including the inferior or superior vena cava, fluoroscopic guidance, with all angioplasty in the central dialysis segment, and transcatheter placement of intravascular stent(s), central dialysis segment, performed through dialysis circuit, including all required imaging, radiological supervision and interpretation, image documentation and report |
| C7515 | Dialysis circuit, introduction of needle(s) and/or catheter(s), with diagnostic angiography of the dialysis circuit, including all direct puncture(s) and catheter placement(s), injection(s) of contrast, all necessary imaging from the arterial anastomosis and adjacent artery through entire venous outflow including the inferior or superior vena cava, fluoroscopic guidance, with dialysis circuit permanent endovascular embolization or occlusion of main circuit or any accessory veins, including all required imaging, radiological supervision and interpretation, image documentation and report |
| C7516 | Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, with endoluminal imaging of initial coronary vessel or graft using intravascular ultrasound (ivus) or optical coherence tomography (oct) during diagnostic evaluation and/or therapeutic intervention including imaging supervision, interpretation and report |
| C7517 | Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, with iliac and/or femoral artery angiography, non-selective, bilateral or ipsilateral to catheter insertion, performed at the same time as cardiac catheterization and/or coronary angiography, includes positioning or placement of the catheter in the distal aorta or ipsilateral femoral or iliac artery, injection of dye, production of permanent images, and radiologic supervision and interpretation |

| | |
|--------------|---|
| C7518 | Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation, with catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) including intraprocedural injection(s) for bypass graft angiography with endoluminal imaging of initial coronary vessel or graft using intravascular ultrasound (ivus) or optical coherence tomography (oct) during diagnostic evaluation and/or therapeutic intervention including imaging, supervision, interpretation and report |
| C7519 | Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation, with catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) including intraprocedural injection(s) for bypass graft angiography with intravascular doppler velocity and/or pressure derived coronary flow reserve measurement (initial coronary vessel or graft) during coronary angiography including pharmacologically induced stress |
| C7520 | Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation, with catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) includes intraprocedural injection(s) for bypass graft angiography with iliac and/or femoral artery angiography, non-selective, bilateral or ipsilateral to catheter insertion, performed at the same time as cardiac catheterization and/or coronary angiography, includes positioning or placement of the catheter in the distal aorta or ipsilateral femoral or iliac artery, injection of dye, production of permanent images, and radiologic supervision and interpretation |
| C7521 | Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography with right heart catheterization with endoluminal imaging of initial coronary vessel or graft using intravascular ultrasound (ivus) or optical coherence tomography (oct) during diagnostic evaluation and/or therapeutic intervention including imaging supervision, interpretation and report |
| C7522 | Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation with right heart catheterization, with intravascular doppler velocity and/or pressure derived coronary flow reserve measurement (initial coronary vessel or graft) during coronary angiography including pharmacologically induced stress |
| C7523 | Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation, with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, with endoluminal imaging of initial coronary vessel or graft using intravascular ultrasound (ivus) or optical coherence tomography (oct) during diagnostic evaluation and/or therapeutic intervention including imaging supervision, interpretation and report |
| C7524 | Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation, with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, with intravascular doppler velocity and/or pressure derived coronary flow reserve measurement (initial coronary vessel or graft) during coronary angiography including pharmacologically induced stress |
| C7525 | Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation, with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) with bypass graft angiography with endoluminal imaging of initial coronary vessel or graft using intravascular ultrasound (ivus) or optical coherence tomography (oct) during diagnostic evaluation and/or therapeutic intervention including imaging supervision, interpretation and report |

| | |
|--------------|--|
| C7526 | Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation, with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) with bypass graft angiography with intravascular doppler velocity and/or pressure derived coronary flow reserve measurement (initial coronary vessel or graft) during coronary angiography including pharmacologically induced stress |
| C7527 | Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation, with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, with endoluminal imaging of initial coronary vessel or graft using intravascular ultrasound (ivus) or optical coherence tomography (oct) during diagnostic evaluation and/or therapeutic intervention including imaging supervision, interpretation and report |
| C7528 | Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation, with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, with intravascular doppler velocity and/or pressure derived coronary flow reserve measurement (initial coronary vessel or graft) during coronary angiography including pharmacologically induced stress |
| C7529 | Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation, with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) with bypass graft angiography with intravascular doppler velocity and/or pressure derived coronary flow reserve measurement (initial coronary vessel or graft) during coronary angiography including pharmacologically induced stress |
| C7530 | Dialysis circuit, introduction of needle(s) and/or catheter(s), with diagnostic angiography of the dialysis circuit, including all direct puncture(s) and catheter placement(s), injection(s) of contrast, all necessary imaging from the arterial anastomosis and adjacent artery through entire venous outflow including the inferior or superior vena cava, fluoroscopic guidance, with transluminal balloon angioplasty, peripheral dialysis segment, including all imaging and radiological supervision and interpretation necessary to perform the angioplasty and all angioplasty in the central dialysis segment, with transcatheter placement of intravascular stent(s), central dialysis segment, performed through dialysis circuit, including all imaging, radiological supervision and interpretation, documentation and report |
| C7531 | Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(ies), unilateral, with transluminal angioplasty with intravascular ultrasound (initial noncoronary vessel) during diagnostic evaluation and/or therapeutic intervention, including radiological supervision and interpretation |
| C7532 | Transluminal balloon angioplasty (except lower extremity artery(ies) for occlusive disease, intracranial, coronary, pulmonary, or dialysis circuit), initial artery, open or percutaneous, including all imaging and radiological supervision and interpretation necessary to perform the angioplasty within the same artery, with intravascular ultrasound (initial noncoronary vessel) during diagnostic evaluation and/or therapeutic intervention, including radiological supervision and interpretation |
| C7533 | Percutaneous transluminal coronary angioplasty, single major coronary artery or branch with transcatheter placement of radiation delivery device for subsequent coronary intravascular brachytherapy |

| | |
|--------------|---|
| C7545 | Percutaneous exchange of biliary drainage catheter (eg, external, internal-external, or conversion of internal-external to external only), with removal of calculi/debris from biliary duct(s) and/or gallbladder, including destruction of calculi by any method (eg, mechanical, electrohydraulic, lithotripsy) when performed, including diagnostic cholangiography(ies) when performed, imaging guidance (eg, fluoroscopy), and all associated radiological supervision and interpretation |
| C7546 | Removal and replacement of externally accessible nephroureteral catheter (eg, external/internal stent) requiring fluoroscopic guidance, with ureteral stricture balloon dilation, including imaging guidance and all associated radiological supervision and interpretation |
| C7547 | Convert nephrostomy catheter to nephroureteral catheter, percutaneous via pre-existing nephrostomy tract, with ureteral stricture balloon dilation, including diagnostic nephrostogram and/or ureterogram when performed, imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation |
| C7548 | Exchange nephrostomy catheter, percutaneous, with ureteral stricture balloon dilation, including diagnostic nephrostogram and/or ureterogram when performed, imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation |
| C7549 | Change of ureterostomy tube or externally accessible ureteral stent via ileal conduit with ureteral stricture balloon dilation, including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation |
| C7550 | Cystourethroscopy, with biopsy(ies) with adjunctive blue light cystoscopy with fluorescent imaging agent |
| C7551 | Excision of major peripheral nerve neuroma, except sciatic, with implantation of nerve end into bone or muscle |
| C7552 | Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) including intraprocedural injection(s) for bypass graft angiography and right heart catheterization with intravascular doppler velocity and/or pressure derived coronary flow reserve measurement (coronary vessel or graft) during coronary angiography including pharmacologically induced stress, initial vessel |
| C7553 | Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) with bypass graft angiography with pharmacologic agent administration (eg, inhaled nitric oxide, intravenous infusion of nitroprusside, dobutamine, milrinone, or other agent) including assessing hemodynamic measurements before, during, after and repeat pharmacologic agent administration, when performed |
| C7554 | Cystourethroscopy with adjunctive blue light cystoscopy with fluorescent imaging agent |
| C9144 | Injection, bupivacaine (posimir), 1 mg |
| G0322 | The collection of physiologic data digitally stored and/or transmitted by the patient to the home health agency (i.e., remote patient monitoring) |
| J0173 | Injection, epinephrine (belcher) not therapeutically equivalent to j0171, 0.1 mg |
| M0001 | Advancing cancer care mips value pathways |
| M0002 | Optimal care for kidney health mips value pathways |
| M0003 | Optimal care for patients with episodic neurological conditions mips value pathways |
| M0004 | Supportive care for neurodegenerative conditions mips value pathways |
| M0005 | Promoting wellness mips value pathways |

| | |
|--------------|--|
| MI150 | Left ventricular ejection fraction (lvef) less than or equal to 40% or documentation of moderately or severely depressed left ventricular systolic function |
| MI151 | Patients with a history of heart transplant or with a left ventricular assist device (lvad) |
| MI152 | Patients with a history of heart transplant or with a left ventricular assist device (lvad) |
| MI153 | Patient with diagnosis of osteoporosis on date of encounter |
| MI154 | Hospice services provided to patient any time during the measurement period |
| MI155 | Patient had anaphylaxis due to the pneumococcal vaccine any time during or before the measurement period |
| MI156 | Patient received active chemotherapy any time during the measurement period |
| MI157 | Patient received bone marrow transplant any time during the measurement period |
| MI158 | Patient had history of immunocompromising conditions prior to or during the measurement period |
| MI159 | Hospice services provided to patient any time during the measurement period |
| MI160 | Patient had anaphylaxis due to the meningococcal vaccine any time on or before the patient's 13th birthday |
| MI161 | Patient had anaphylaxis due to the tetanus, diphtheria or pertussis vaccine any time on or before the patient's 13th birthday |
| MI162 | Patient had encephalitis due to the tetanus, diphtheria or pertussis vaccine any time on or before the patient's 13th birthday |
| MI163 | Patient had anaphylaxis due to the hpv vaccine any time on or before the patient's 13th birthday |
| MI164 | Patients with dementia any time during the patient's history through the end of the measurement period |
| MI165 | Patients who use hospice services any time during the measurement period |
| MI166 | Pathology report for tissue specimens produced from wide local excisions or re-excisions |
| MI167 | In hospice or using hospice services during the measurement period |
| MI168 | Patient received an influenza vaccine on or between July 1 of the year prior to the measurement period and June 30 of the measurement period |
| MI169 | Documentation of medical reason(s) for not administering influenza vaccine (e.g., prior anaphylaxis due to the influenza vaccine) |
| MI170 | Patient did not receive an influenza vaccine on or between July 1 of the year prior to the measurement period and June 30 of the measurement period |
| MI171 | Patient received at least one td vaccine or one tdap vaccine between nine years prior to the encounter and the end of the measurement period |
| MI172 | Documentation of medical reason(s) for not administering td or tdap vaccine (e.g., prior anaphylaxis due to the td or tdap vaccine or history of encephalopathy within seven days after a previous dose of a td-containing vaccine) |
| MI173 | Patient did not receive at least one td vaccine or one tdap vaccine between nine years prior to the encounter and the end of the measurement period |
| MI174 | Patient received at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period |
| MI175 | Documentation of medical reason(s) for not administering zoster vaccine (e.g., prior anaphylaxis due to the zoster vaccine) |
| MI176 | Patient did not receive at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period |
| MI177 | Patient received any pneumococcal conjugate or polysaccharide vaccine on or after their 60th birthday and before the end of the measurement period |

| | |
|--------------|--|
| MI178 | Documentation of medical reason(s) for not administering pneumococcal vaccine (e.g., prior anaphylaxis due to the pneumococcal vaccine) |
| MI179 | Patient did not receive any pneumococcal conjugate or polysaccharide vaccine, on or after their 60th birthday and before or during measurement period |
| MI180 | Patients on immune checkpoint inhibitor therapy |
| MI181 | Grade 2 or above diarrhea and/or grade 2 or above colitis |
| MI182 | Patients not eligible due to pre-existing inflammatory bowel disease (ibd) (e.g., ulcerative colitis, crohn's disease) |
| MI183 | Documentation of immune checkpoint inhibitor therapy held and corticosteroids or immunosuppressants prescribed or administered |
| MI184 | Documentation of medical reason(s) for not prescribing or administering corticosteroid or immunosuppressant treatment (e.g., allergy, intolerance, infectious etiology, pancreatic insufficiency, hyperthyroidism, prior bowel surgical interventions, celiac disease, receiving other medication, awaiting diagnostic workup results for alternative etiologies, other medical reasons/contraindication) |
| MI185 | Documentation of immune checkpoint inhibitor therapy not held and/or corticosteroids or immunosuppressants prescribed or administered was not performed, reason not given |
| MI186 | Patients who have an order for or are receiving hospice or palliative care |
| MI187 | Patients with a diagnosis of end stage renal disease (esrd) |
| MI188 | Patients with a diagnosis of chronic kidney disease (ckd) stage 5 |
| MI189 | Documentation of a kidney health evaluation defined by an estimated glomerular filtration rate (egfr) and urine albumin-creatinine ratio (uacr) performed |
| MI190 | Documentation of a kidney health evaluation was not performed or defined by an estimated glomerular filtration rate (egfr) and urine albumin-creatinine ratio (uacr) |
| MI191 | Hospice services provided to patient any time during the measurement period |
| MI192 | Patients with an existing diagnosis of squamous cell carcinoma of the esophagus |
| MI193 | Surgical pathology reports that contain impression or conclusion of or recommendation for testing of mmr by immunohistochemistry, msi by dna-based testing status, or both |
| MI194 | Documentation of medical reason(s) surgical pathology reports did not contain impression or conclusion of or recommendation for testing of mmr by immunohistochemistry, msi by dna-based testing status, or both tests were not included (e.g., patient will not be treated with checkpoint inhibitor therapy, no residual carcinoma is present in the sample [tissue exhausted or status post neoadjuvant treatment], insufficient tumor for testing) |
| MI195 | Surgical pathology reports that do not contain impression or conclusion of or recommendation for testing of mmr by immunohistochemistry, msi by dna-based testing status, or both, reason not given |
| MI196 | Initial (index visit) numeric rating scale (nrs), visual rating scale (vrs), or itchyquant assessment score of greater than or equal to 4 |
| MI197 | Itch severity assessment score is reduced by 2 or more points from the initial (index) assessment score to the follow-up visit score |
| MI198 | Itch severity assessment score was not reduced by at least 2 points from initial (index) score to the follow-up visit score or assessment was not completed during the follow-up encounter |
| MI199 | Patients receiving rrt |
| MI200 | Ace inhibitor (ace-i) or arb therapy prescribed during the measurement period |

| | |
|----------------|---|
| MI201 | Documentation of medical reason(s) for not prescribing ace inhibitor (ace-i) or arb therapy during the measurement period (e.g., pregnancy, history of angioedema to ace-i, other allergy to ace-i and arb, hyperkalemia or history of hyperkalemia while on ace-i or arb therapy, acute kidney injury due to ace-i or arb therapy), other medical reasons) |
| MI202 | Documentation of patient reason(s) for not prescribing ace inhibitor or arb therapy during the measurement period, (e.g., patient declined, other patient reasons) |
| MI203 | Ace inhibitor or arb therapy not prescribed during the measurement period; reason not given |
| MI204 | Initial (index visit) numeric rating scale (nrs), visual rating scale (vrs), or itchyquant assessment score of greater than or equal to 4 |
| MI205 | Itch severity assessment score is reduced by 2 or more points from the initial (index) assessment score to the follow-up visit score |
| MI206 | Itch severity assessment score was not reduced by at least 2 points from initial (index) score to the follow-up visit score or assessment was not completed during the follow-up encounter |
| MI207 | Number of patients screened for food insecurity, housing instability, transportation needs, utility difficulties, and interpersonal safety |
| MI208 | Number of patients not screened for food insecurity, housing instability, transportation needs, utility difficulties, and interpersonal safety |
| MI209 | At least two orders for high-risk medications from the same drug class, (table 4), not ordered |
| MI210 | At least two orders for high-risk medications from the same drug class, (table 4), not ordered |
| Q4262 | Dual layer impax membrane, per square centimeter |
| Q4263 | Surgraft tl, per square centimeter |
| Q4264 | Cocoon membrane, per square centimeter |
| Z55.6 | Problems related to health literacy |
| Z59.10 | Inadequate housing, unspecified |
| Z59.11 | Inadequate housing environmental temperature |
| Z59.12 | Inadequate housing utilities |
| Z59.19 | Other inadequate housing |
| Z91.141 | Patient's other noncompliance with medication regimen due to financial hardship |
| Z91.148 | Patient's other noncompliance with medication regimen for other reason |
| Z91.151 | Patient's noncompliance with renal dialysis due to financial hardship |
| Z91.158 | Patient's noncompliance with renal dialysis for other reason |

[Back to top](#)

Table 8 – Deleted Codes

| Code | Desc | Effective Date | Replacement Code (if applicable) |
|--------------|--|-----------------------|---|
| 15850 | Removal of sutures under anesthesia by same surgeon | 12/31/2022 | 15851 |
| 49560 | Repair of incisional or abdominal hernia | 12/31/2022 | 49591-49596 |
| 49561 | Repair of trapped incisional or abdominal hernia | 12/31/2022 | 49591-49596 |
| 49565 | Repair of recurrent incisional or abdominal hernia | 12/31/2022 | 49613, 49614, 49615, 49616, 49617, 49618 |
| 49566 | Repair of trapped recurrent incisional or abdominal hernia | 12/31/2022 | 49613, 49614, 49615, 49616, 49617, 49618 |
| 49568 | Placement of mesh to repair incisional or abdominal hernia | 12/31/2022 | 49591-49596, 49600, 49605, 49606, 49610-49611, 49613, 49614, 49615, 49616, 49617, 49618 |
| 49570 | Repair of incisional or abdominal hernia in upper stomach area | 12/31/2022 | 49591-49596, 49600, 49605, 49606, 49610-49611, 49613, 49614, 49615, 49616, 49617, 49618 |
| 49572 | Repair of trapped incisional or abdominal hernia in upper stomach area | 12/31/2022 | 49591-49596, 49600, 49605, 49606, 49610-49611, 49613, 49614, 49615, 49616, 49617, 49618 |
| 49580 | Repair of hernia at navel (younger than 5 years) | 12/31/2022 | 49591-49596, 49600, 49605, 49606, 49610-49611, 49613, 49614, 49615, 49616, 49617, 49618 |
| 49582 | Repair of trapped hernia at navel (younger than 5 years) | 12/31/2022 | 49591-49596, 49600, 49605, 49606, 49610-49611, 49613, 49614, 49615, 49616, 49617, 49618 |
| 49585 | Repair of hernia at navel (5 years or older) | 12/31/2022 | 49591-49596, 49600, 49605, 49606, 49610-49611, 49613, 49614, 49615, 49616, 49617, 49618 |
| 49587 | Repair of trapped hernia at navel (5 years or older) | 12/31/2022 | 49591-49596, 49600, 49605, 49606, 49610-49611, 49613, 49614, 49615, 49616, 49617, 49618 |
| 49590 | Repair of hernia between abdominal muscles | 12/31/2022 | 49591-49596, 49600, 49605, 49606, 49610-49611, 49613, 49614, 49615, 49616, 49617, 49618 |

| | | | |
|--------------|---|------------|---|
| 49652 | Repair of hernia using an endoscope | 12/31/2022 | 49591-49596, 49600, 49605, 49606, 49610-49611, 49613, 49614, 49615, 49616, 49617, 49618 |
| 49653 | Repair of trapped hernia using an endoscope | 12/31/2022 | 49591-49596, 49600, 49605, 49606, 49610-49611, 49613, 49614, 49615, 49616, 49617, 49618 |
| 49654 | Repair of incisional hernia using an endoscope | 12/31/2022 | 49591-49596, 49600, 49605, 49606, 49610-49611, 49613, 49614, 49615, 49616, 49617, 49618 |
| 49655 | Repair of trapped incisional hernia using an endoscope | 12/31/2022 | 49591-49596, 49600, 49605, 49606, 49610-49611, 49613, 49614, 49615, 49616, 49617, 49618 |
| 49656 | Repair of recurrent incisional hernia using an endoscope | 12/31/2022 | 49613, 49614, 49615, 49616, 49617, 49618 |
| 49657 | Repair of recurrent trapped incisional hernia using an endoscope | 12/31/2022 | 49613, 49614, 49615, 49616, 49617, 49618 |
| 99217 | Hospital observation care on day of discharge | 12/31/2022 | 99238-99239 |
| 99218 | Initial hospital observation care per day, typically 30 minutes | 12/31/2022 | 99221-99223 |
| 99219 | Initial hospital observation care per day, typically 50 minutes | 12/31/2022 | 99221-99223 |
| 99220 | Initial hospital observation care per day, typically 70 minutes | 12/31/2022 | 99221-99223 |
| 99224 | Follow-up observation care per day, typically 15 minutes | 12/31/2022 | 99231-99233 |
| 99225 | Follow-up observation care per day, typically 25 minutes | 12/31/2022 | 99231-99233 |
| 99226 | Follow-up observation care per day, typically 35 minutes | 12/31/2022 | 99231-99233 |
| 99241 | Office consultation, typically 15 minutes | 12/31/2022 | 99242 |
| 99251 | Inpatient hospital consultation, typically 20 minutes | 12/31/2022 | 99252 |
| 99318 | Nursing facility annual assessment, typically 30 minutes | 12/31/2022 | 99307-99310 |
| 99324 | New patient custodial care facility, group care, or assisted living visit, typically 20 minutes | 12/31/2022 | 99341-99345 |
| 99325 | New patient custodial care facility, group care, or assisted living visit, typically 30 minutes | 12/31/2022 | 99341-99345 |
| 99326 | New patient custodial care facility, group care, or assisted living visit, typically 45 minutes | 12/31/2022 | 99341-99345 |
| 99327 | New patient custodial care facility, group care, or assisted living visit, typically 1 hour | 12/31/2022 | 99341-99345 |
| 99328 | New patient custodial care facility, group care, or assisted living visit, typically 75 minutes | 12/31/2022 | 99341-99345 |

| | | | |
|--------------|--|------------|----------------------------|
| 99334 | Established patient custodial care facility, group care, or assisted living visit, typically 15 minutes | 12/31/2022 | 99347-99350 |
| 99335 | Established patient custodial care facility, group care, or assisted living visit, typically 25 minutes | 12/31/2022 | 99347-99350 |
| 99336 | Established patient custodial care facility, group care, or assisted living visit, typically 40 minutes | 12/31/2022 | 99347-99350 |
| 99337 | Established patient custodial care facility, group care, or assisted living visit, typically 1 hour | 12/31/2022 | 99347-99350 |
| 99339 | Home or assisted living facility physician supervision of care per month, 15-29 minutes | 12/31/2022 | 99437, 99491, 99424, 99425 |
| 99340 | Home or assisted living facility physician supervision of care per month, 30 minutes or more | 12/31/2022 | 99437, 99491, 99424, 99425 |
| 99343 | New patient home visit, typically 45 minutes | 12/31/2022 | 99341-99345 |
| 99354 | Extended office or other outpatient service, first hour | 12/31/2022 | 99417 |
| 99355 | Extended office or other outpatient service, each additional 30 minutes | 12/31/2022 | 99417 |
| 99356 | Extended inpatient or observation hospital service, first hour | 12/31/2022 | 99418 |
| 99357 | Extended inpatient or observation hospital service, each additional 30 minutes | 12/31/2022 | 99418 |
| 0163T | Insertion of lower spine artificial disc, anterior approach | 12/31/2022 | 22857-22860 |
| 0312T | Implantation of neurostimulator electrodes and pulse generator for vagus nerve blocking therapy for obesity using an endoscope | 12/31/2022 | 64999 |
| 0313T | Revision or replacement of neurostimulator electrodes for vagus nerve blocking therapy for obesity using an endoscope | 12/31/2022 | 64999 |
| 0314T | Removal of neurostimulator electrodes and pulse generator for vagus nerve blocking therapy for obesity using an endoscope | 12/31/2022 | 64999 |
| 0315T | Removal of pulse generator for vagus nerve blocking therapy for treatment of obesity | 12/31/2022 | 64999 |
| 0316T | Replacement of pulse generator for vagus nerve blocking therapy for treatment of obesity | 12/31/2022 | 64999 |
| 0317T | Pulse generator analysis of a vagus nerve blocking therapy system for treatment of obesity | 12/31/2022 | 64999 |
| 0470T | OCT scan of skin lesion with interpretation and report, first lesion | 12/31/2022 | 96999 |
| 0471T | OCT scan of skin lesion with interpretation and report, each additional lesion | 12/31/2022 | 96999 |
| 0475T | Recording of fetal magnetic heart signal with technical analysis and interpretation of report | 12/31/2022 | 93799 |
| 0476T | Recording of fetal magnetic heart signal with electronic signal transfer of data and storage | 12/31/2022 | 93799 |

| | | | |
|--------------|--|------------|-------|
| 0477T | Recording of fetal magnetic heart signal with signal extraction, technical analysis, and result | 12/31/2022 | 93799 |
| 0478T | Recording of fetal magnetic heart signal with review and interpretation of report | 12/31/2022 | 93799 |
| 0487T | Biomechanical mapping accessed through the vagina | 12/31/2022 | 58999 |
| 0491T | Laser treatment of open wound, first 20 sq cm or less | 12/31/2022 | 17999 |
| 0492T | Laser treatment of open wound, each additional 20 sq cm | 12/31/2022 | 17999 |
| 0493T | Contact near-infrared spectroscopy of wound of leg | 12/31/2022 | 93998 |
| 0497T | Connection of external patient-activated EKG event recorder | 12/31/2022 | 93799 |
| 0498T | Review and interpretation of external patient-activated EKG event recordings | 12/31/2022 | 93799 |
| 0499T | Examination of bladder and urethra with mechanical dilation and drug delivery for narrowing of urethra using an endoscope | 12/31/2022 | |
| 0514T | Visual axis identification using patient fixation during operation | 12/31/2022 | |
| 0702T | Supply and technical support for remote therapeutic monitoring of standardized online digital cognitive behavioral therapy program, per 30 days | 12/31/2022 | 98978 |
| 0703T | Management services for remote therapeutic monitoring of standardized online digital cognitive behavioral therapy program, per 30 days | 12/31/2022 | 98978 |
| C1849 | Skin substitute, synthetic, resorbable, per square centimeter | 12/31/2022 | |
| C9142 | Injection, bevacizumab-maly, biosimilar, (alymysys), 10 mg | 12/31/2022 | Q5126 |
| G0028 | Documentation of medical reason(s) for not screening for tobacco use (e.g., limited life expectancy, other medical reason) | 12/31/2022 | |
| G0308 | Creation of subcutaneous pocket with insertion of 180 day implantable interstitial glucose sensor, including system activation and patient training | 12/31/2022 | |
| G0309 | Removal of implantable interstitial glucose sensor with creation of subcutaneous pocket at different anatomic site and insertion of new 180 day implantable sensor, including system activation | 12/31/2022 | |
| G2095 | Documentation of system reason(s) for not prescribing ace inhibitor or arb or arni therapy (e.g., other system reasons) | 12/31/2022 | |
| G2170 | Percutaneous arteriovenous fistula creation (avf), direct, any site, by tissue approximation using thermal resistance energy, and secondary procedures to redirect blood flow (e.g., transluminal balloon angioplasty, coil embolization) when performed, and includes all imaging and radiologic guidance, supervision and interpretation, when performed | 12/31/2022 | 36836 |

| | | | |
|--------------|---|------------|-------|
| G2171 | Percutaneous arteriovenous fistula creation (avf), direct, any site, using magnetic-guided arterial and venous catheters and radiofrequency energy, including flow-directing procedures (e.g., vascular coil embolization with radiologic supervision and interpretation, when performed) and fistulogram(s), angiography, enography, and/or ultrasound, with radiologic supervision and interpretation, when performed | 12/31/2022 | 36837 |
| G2198 | Documentation of medical reason(s) for not screening for unhealthy alcohol use using a systematic screening method (e.g., limited life expectancy, other medical reasons) | 12/31/2022 | |
| G2201 | Documentation of medical reason(s) for not providing brief counseling (e.g., limited life expectancy, other medical reasons) | 12/31/2022 | |
| G2203 | Documentation of medical reason(s) for not providing brief counseling if identified as an unhealthy alcohol user (e.g., limited life expectancy, other medical reasons) | 12/31/2022 | |
| G9196 | Documentation of medical reason(s) for not ordering a first or second generation cephalosporin for antimicrobial prophylaxis (e.g., patients enrolled in clinical trials, patients with documented infection prior to surgical procedure of interest, patients who were receiving antibiotics more than 24 hours prior to surgery [except colon surgery patients taking oral prophylactic antibiotics], patients who were receiving antibiotics within 24 hours prior to arrival [except colon surgery patients taking oral prophylactic antibiotics], other medical reason(s)) | 12/31/2022 | |
| G9197 | Documentation of order for first or second generation cephalosporin for antimicrobial prophylaxis | 12/31/2022 | |
| G9198 | Order for first or second generation cephalosporin for antimicrobial prophylaxis was not documented, reason not given | 12/31/2022 | |
| G9250 | Documentation of patient pain brought to a comfortable level within 48 hours from initial assessment | 12/31/2022 | |
| G9251 | Documentation of patient with pain not brought to a comfortable level within 48 hours from initial assessment | 12/31/2022 | |
| G9359 | Documentation of negative or managed positive tb screen with further evidence that tb is not active prior to treatment with a biologic immune response modifier | 12/31/2022 | |
| G9360 | No documentation of negative or managed positive tb screen | 12/31/2022 | |
| G9506 | Biologic immune response modifier prescribed | 12/31/2022 | |
| G9618 | Documentation of screening for uterine malignancy or those that had an ultrasound and/or endometrial sampling of any kind | 12/31/2022 | |
| G9620 | Patient not screened for uterine malignancy, or those that have not had an ultrasound and/or endometrial sampling of any kind, reason not given | 12/31/2022 | |
| G9623 | Documentation of medical reason(s) for not screening for unhealthy alcohol use (e.g., limited life expectancy, other medical reasons) | 12/31/2022 | |

| | | | |
|--------------|---|------------|--|
| G9631 | Patient sustained ureter injury at the time of surgery or discovered subsequently up to 30 days post-surgery | 12/31/2022 | |
| G9632 | Documented medical reasons for not reporting ureter injury (e.g., gynecologic or other pelvic malignancy documented, concurrent surgery involving bladder pathology, injury that occurs during a urinary incontinence procedure, patient death from non-medical causes not related to surgery, patient died during procedure without evidence of ureter injury) | 12/31/2022 | |
| G9633 | Patient did not sustain ureter injury at the time of surgery nor discovered subsequently up to 30 days post-surgery | 12/31/2022 | |
| G9718 | Hospice services for patient provided any time during the measurement period | 12/31/2022 | |
| G9774 | Patients who have had a hysterectomy | 12/31/2022 | |
| G9778 | Patients who have a diagnosis of pregnancy at any time during the measurement period | 12/31/2022 | |
| G9808 | Any patients who had no asthma controller medications dispensed during the measurement year | 12/31/2022 | |
| G9809 | Patients who use hospice services any time during the measurement period | 12/31/2022 | |
| G9810 | Patient achieved a pdc of at least 75% for their asthma controller medication | 12/31/2022 | |
| G9811 | Patient did not achieve a pdc of at least 75% for their asthma controller medication | 12/31/2022 | |
| G9904 | Documentation of medical reason(s) for not screening for tobacco use (e.g., limited life expectancy, other medical reason) | 12/31/2022 | |
| G9907 | Documentation of medical reason(s) for not providing tobacco cessation intervention on the date of the encounter or within the previous 12 months (e.g., limited life expectancy, other medical reason) | 12/31/2022 | |
| G9909 | Documentation of medical reason(s) for not providing tobacco cessation intervention on the date of the encounter or within the previous 12 months if identified as a tobacco user (e.g., limited life expectancy, other medical reason) | 12/31/2022 | |
| G9932 | Documentation of patient reason(s) for not having records of negative or managed positive tb screen (e.g., patient does not return for mantoux (ppd) skin test evaluation) | 12/31/2022 | |
| G9942 | Patient had any additional spine procedures performed on the same date as the lumbar discectomy/laminectomy | 12/31/2022 | |
| G9948 | Patient had any additional spine procedures performed on the same date as the lumbar discectomy/laminectomy | 12/31/2022 | |
| G9989 | Documentation of medical reason(s) for not administering pneumococcal vaccine (e.g., adverse reaction to vaccine) | 12/31/2022 | |

| | | | |
|--------------|--|------------|----------------------------|
| J2400 | Injection, chlorprocaine hydrochloride, per 30 ml | 12/31/2022 | J2401, J2402 |
| J9044 | Injection, bortezomib, not otherwise specified, 0.1 mg | 12/31/2022 | J9041, J9046, J9048, J9049 |
| K0553 | Supply allowance for therapeutic continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service | 12/31/2022 | |
| K0554 | Receiver (monitor), dedicated, for use with therapeutic glucose continuous monitor system | 12/31/2022 | |
| MI017 | Patient admitted to palliative care services | 12/31/2022 | |
| MI071 | Patient had any additional spine procedures performed on the same date as the lumbar discectomy/laminotomy | 12/31/2022 | |

[Back to top](#)